JFL Life Sciences (NSE:JFLLIFE) Operating Income: ₹72.1 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:JFLLIFE JFL Life Sciences Ltd NSE:JFLLIFE
73 GF Score
Price ₹13.65
GF Value ₹36.35
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is JFL Life Sciences Operating Income?

JFL Life Sciences NSE:JFLLIFE +4.20% 73 Operating Income is ₹72.1 Mil as of Mar. 2025. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 73/100 and a GF Value™ of ₹36.35 (Significantly Undervalued). The stock has 3 warning signs investors should review.

JFL Life Sciences's Operating Income for the six months ended in Mar. 2025 was ₹72.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ₹72.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. JFL Life Sciences's Operating Income for the six months ended in Mar. 2025 was ₹72.1 Mil. JFL Life Sciences's Revenue for the six months ended in Mar. 2025 was ₹820.4 Mil. Therefore, JFL Life Sciences's Operating Margin % for the quarter that ended in Mar. 2025 was 8.78%.

Good Sign:

JFL Life Sciences Ltd operating margin is expanding. Margin expansion is usually a good sign.

JFL Life Sciences's 5-Year average Growth Rate for Operating Margin % was 9.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2025 was 10.39%. JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 15.61%.


JFL Life Sciences  (NSE:JFLLIFE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=72.065 * ( 1 - 32.22% )/( (424.144 + 515.892)/ 2 )
=48.845657/470.018
=10.39 %

where

Note: The Operating Income data used here is one times the annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=71.282/( ( (128.334 + max(282.026, 0)) + (122.363 + max(380.574, 0)) )/ 2 )
=71.282/( ( 410.36 + 502.937 )/ 2 )
=71.282/456.6485
=15.61 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(258.466 + 158.333 + 18.609) - (142.618 + 0 + 10.764)
=282.026

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(349.451 + 232.411 + 12.823) - (202.909 + 0 + 11.202)
=380.574

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

JFL Life Sciences's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=72.065/820.423
=8.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


JFL Life Sciences Operating Income Related Terms


JFL Life Sciences Operating Income Historical Data

* Premium members only.

The historical data trend for JFL Life Sciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences Operating Income Chart

JFL Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Operating Income
Get a 7-Day Free Trial 18.86 49.80 35.02 41.89 72.07

JFL Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Operating Income Get a 7-Day Free Trial 18.86 49.80 35.02 41.89 72.07
NSE:JFLLIFE
73GF Score
JFL Life Sciences Ltd NSE:JFLLIFE
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JFL Life Sciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ₹72.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹72.1 Mil mean?
JFL Life Sciences (NSE:JFLLIFE) has a Operating Income of ₹72.1 Mil as of Mar. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on JFL Life Sciences and its competitors.
Is JFL Life Sciences' Operating Income too high?
JFL Life Sciences' current Operating Income is ₹72.1 Mil. Overall, JFL Life Sciences has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Operating Income compare to ZTS?
JFL Life Sciences' Operating Income of ₹72.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on JFL Life Sciences and its competitors. JFL Life Sciences's current Operating Income is ₹72.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹36.35, compared to a current price of ₹13.65 — trading 62.4% below its estimated fair value. The current Operating Income is ₹72.1 Mil. JFL Life Sciences' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Operating Income is ₹72.1 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued. The current stock price of ₹13.65 is trading 62.4% below its estimated GF Value™ of ₹36.35. GuruFocus considers JFL Life Sciences to be Significantly Undervalued.

Key valuation signals for NSE:JFLLIFE:

  • Operating Income: ₹72.1 Mil
  • GF Value™: ₹36.35 vs. price of ₹13.65 (62.4% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JFL Life Sciences Business Description

Address Jodhpur Cross Road, 309, Satyam Mall, Opposite Saman Complex, Near Vishweshwar Mahadev Mandir, Settelite, Ahmedabad, GJ, IND, 380015
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
73GF Score

Get the complete analysis for NSE:JFLLIFE

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.65
Price
₹36.35
GF Value